Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 57.0% in May

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 48,500 shares, a growth of 57.0% from the May 15th total of 30,900 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is currently 0.5 days.

Analyst Ratings Changes

A number of equities research analysts have issued reports on KMDA shares. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Thursday, March 6th. Wall Street Zen upgraded Kamada from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 21st. Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Kamada in a research note on Thursday, May 15th. Finally, Sidoti raised Kamada to a “hold” rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kamada currently has a consensus rating of “Buy” and a consensus target price of $14.67.

Kamada Price Performance

NASDAQ KMDA traded up $0.27 during trading hours on Monday, hitting $7.15. The company’s stock had a trading volume of 90,056 shares, compared to its average volume of 93,845. The company has a market cap of $411.16 million, a P/E ratio of 25.54, a price-to-earnings-growth ratio of 0.97 and a beta of 0.94. The company’s 50 day simple moving average is $6.65 and its two-hundred day simple moving average is $6.73. Kamada has a 12 month low of $4.74 and a 12 month high of $9.16.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The firm had revenue of $44.02 million for the quarter, compared to analysts’ expectations of $154.06 million. Kamada had a net margin of 9.92% and a return on equity of 6.30%. As a group, research analysts predict that Kamada will post 0.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kamada

A number of hedge funds have recently modified their holdings of the company. Huntleigh Advisors Inc. bought a new position in Kamada in the 1st quarter worth approximately $863,000. Jane Street Group LLC bought a new stake in shares of Kamada in the 1st quarter valued at approximately $582,000. Goldman Sachs Group Inc. purchased a new position in Kamada during the first quarter worth $497,000. Aristides Capital LLC raised its stake in shares of Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of Kamada by 119.9% in the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.